ProCE Banner Activity

Tebentafusp ± Durvalumab and/or Tremelimumab in Metastatic Cutaneous Melanoma: Updated OS Analysis From IMCgp100-201 Trial

Slideset Download
Conference Coverage
In this updated analysis of patients with PD-/PD-L1–treated metastatic cutaneous melanoma, tebentafusp, a bispecific therapy targeting gp100 and CD3, plus anti–PD-L1 was associated with a promising 1-year OS rate of 75%.

Released: June 13, 2022

Expiration: June 12, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab